X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-09-05 | ATHA | Gengos Andrew | CFO, CHIEF BUSINESS OFFICER | S - Sale | $0.57 | -1,272 | 97,532 | -1% | -$720 | ||||||
2024-09-05 | ATHA | Lenington Rachel | COO, CDO | S - Sale | $0.57 | -2,525 | 20,870 | -11% | -$1,429 | ||||||
2024-09-05 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale | $0.57 | -2,525 | 92,684 | -3% | -$1,429 | ||||||
2024-09-05 | ATHA | Worthington Mark | GC | S - Sale | $0.57 | -2,525 | 51,927 | -5% | -$1,429 | ||||||
2024-09-05 | ATHA | Litton Mark James | Pres, CEO | S - Sale | $0.57 | -5,032 | 179,054 | -3% | -$2,848 | ||||||
| M | 2024-06-21 | ATHA | Romano Kelly A | Dir | P - Purchase | $2.36 | +42,400 | 80,715 | +111% | +$100,051 | |||||
| A | 2024-01-05 | ATHA | Lenington Rachel | COO, CDO | S - Sale | $2.91 | -2,412 | 13,395 | -15% | -$7,019 | |||||
| A | 2024-01-05 | ATHA | Litton Mark James | CEO | S - Sale | $2.91 | -4,820 | 164,086 | -3% | -$14,026 | |||||
| A | 2024-01-05 | ATHA | Worthington Mark | GC | S - Sale | $2.91 | -2,412 | 34,452 | -7% | -$7,019 | |||||
| A | 2024-01-05 | ATHA | Gengos Andrew | CFO, CHIEF BUSINESS OFFICER | S - Sale | $2.91 | -1,208 | 83,804 | -1% | -$3,515 | |||||
| A | 2024-01-05 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale | $2.91 | -2,412 | 80,256 | -3% | -$7,019 | |||||
2023-01-05 | ATHA | Gengos Andrew | See Below | S - Sale | $2.91 | -1,208 | 83,804 | -1% | -$3,515 | ||||||
2024-01-05 | ATHA | Litton Mark James | CEO | S - Sale | $2.91 | -4,820 | 164,086 | -3% | -$14,026 | ||||||
2024-01-05 | ATHA | Worthington Mark | GC | S - Sale | $2.91 | -2,412 | 34,452 | -7% | -$7,019 | ||||||
2023-01-05 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale | $2.91 | -2,412 | 80,256 | -3% | -$7,019 | ||||||
2024-01-05 | ATHA | Lenington Rachel | COO | S - Sale | $2.91 | -2,412 | 13,395 | -15% | -$7,019 | ||||||
| M | 2023-12-27 | ATHA | Perceptive Advisors LLC | Dir, 10% | P - Purchase | $2.42 | +605,686 | 5,402,964 | +13% | +$1,462,895 | |||||
2023-06-07 | ATHA | Gengos Andrew | See Below | P - Purchase | $3.43 | +15,000 | 80,012 | +23% | +$51,445 | ||||||
| M | 2023-06-02 | ATHA | Gengos Andrew | See Below | P - Purchase | $2.95 | +65,012 | 65,012 | New | +$191,572 | |||||
| M | 2023-03-29 | ATHA | Pickering Grant | Dir | P - Purchase | $2.41 | +25,000 | 25,783 | >999% | +$60,350 | |||||
2023-03-29 | ATHA | Johnson James A | Dir | P - Purchase | $2.40 | +5,000 | 5,000 | New | +$12,000 | ||||||
2022-12-28 | ATHA | Mileson Glenna | CFO | P - Purchase | $2.85 | +50,000 | 159,930 | +45% | +$142,250 | ||||||
2022-12-02 | ATHA | Romano Kelly A | Dir | P - Purchase | $3.29 | +30,000 | 38,315 | +361% | +$98,700 | ||||||
2022-11-15 | ATHA | Moebius Hans | Chief Medical Officer | P - Purchase | $3.29 | +5,000 | 65,836 | +8% | +$16,442 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |